Karolien Aelbrecht

Dr. Karolien Aelbrecht

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
+3
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Patient Education and Counseling
Verified
Journal Article
Closed access
KAKarolien Aelbrecht
Karolien Aelbrecht
LHLise Hanssens
Lise Hanssens
JDJens Detollenaere
Jens Detollenaere
SWSara Willems
Sara Willems
MDMyriam Deveugele
Myriam Deveugele
PPPeter Pype
Peter Pype

27 November 2014 in Advances in Health Sciences Education
Verified
Journal Article
Closed access
PDF file
KAKarolien Aelbrecht
Karolien Aelbrecht
MRMichela Rimondini
Michela Rimondini
JBJozien Bensing
Jozien Bensing
FMFrancesca Moretti
Francesca Moretti
SWSara Judith Willems
Sara Judith Willems
MDMyriam Deveugele
Myriam Deveugele

1 October 2016 in Patient Education and Counseling
Verified
Journal Article
Closed access
KAKarolien Aelbrecht
Karolien Aelbrecht
PPPeter Pype
Peter Pype
JVJolien Vos
Jolien Vos
MDMyriam Deveugele
Myriam Deveugele

1 June 2019 in Patient Education and Counseling
Verified
Journal Article
Closed access
Sara RubinelliSara Rubinelli
Sara Rubinelli
JSJonathan Silverman
Jonathan Silverman
KAKarolien Aelbrecht
Karolien Aelbrecht
MDMyriam Deveugele
Myriam Deveugele
AFArnstein Finset
Arnstein Finset
EWEvelyn van Weel-Baumgarten
Evelyn van Weel-Baumgarten

1 October 2017 in Patient Education and Counseling
Verified
Journal Article
Closed access
KAKarolien Aelbrecht
Karolien Aelbrecht
SMStéphanie De Maesschalck
Stéphanie De Maesschalck
SWSara Judith Willems
Sara Judith Willems
MDMyriam Deveugele
Myriam Deveugele
PPPeter Pype
Peter Pype

9 January 2026 in Annales de Dermatologie et de Vénéréologie
Verified
Journal Article
Open access
LML. Martin
L. Martin
WSWilko Spiering
Wilko Spiering
KAKarolien Aelbrecht
Karolien Aelbrecht
TAT. Aranyi
T. Aranyi
CDC. Duranton
C. Duranton
SWS. Willoteaux
S. Willoteaux
Pseudoxanthoma elasticum (PXE) is an autosomal recessive disorder described more than 150 years ago in which calcification and fragmentation of the elastic fibers result in a variety of symptoms which differ greatly in presentation and severity between patients. The diagnosis of PXE can still be made in many patients based on clinical presentation. However, in the advent of genetic screening that followed upon the identification of the first causal gene, ABCC6, milder cases of PXE or patients with a less typical onset of disease surfaced. Moreover, it became clear in the last years that PXE has at least one allelic disorder which can also result from (identical) ABCC6 or ENPP1 pathogenic variants, namely generalized arterial calcification of infancy (GACI). These recent evolutions lead to challenges in making the correct diagnosis in a given number of patients. As emerging possibilities to treat PXE require a definite diagnosis, a critical re-appraisal of the diagnostic criteria for PXE - taking into account new clinical, biochemical and molecular characteristics - appeared to be necessary. The REACT-PXE (Research, Education and Advanced Care Teams for PXE) Consortium - gathering most European experts on PXE - has been established to take on this task as a first step in updating the management of PXE. This paper presents an updated, evidence-based definition of PXE, revised diagnostic criteria, "red flags" for considering PXE, and a patient-centered approach to identifying meaningful outcomes. All skin, ocular, vascular and other disease manifestations are addressed and illustrated, followed by specific chapters on molecular genetics and biological alterations. All these efforts are designed to improve disease management, consider future treatment for all patients, with or without molecular definition of their condition, enhance patient care, and inform for future research directions.